Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Crew, P. Brown, H. Greenlee, T. Bevers, B. Arun, C. Hudis, H. McArthur, Jenny Chang, M. Rimawi, L. Vornik, T. Cornelison, Antai Wang, H. Hibshoosh, Aqeel Ahmed, M. Terry, R. Santella, S. Lippman, D. Hershman (2012)
Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast CancerCancer Prevention Research, 5
Brendan Quinn, H. Kitagawa, R. Memmott, Joell Gills, P. Dennis (2013)
Repositioning metformin for cancer prevention and treatmentTrends in Endocrinology & Metabolism, 24
P. Goodwin, V. Stambolic, J. Lemieux, Bingshu Chen, W. Parulekar, K. Gelmon, D. Hershman, T. Hobday, J. Ligibel, I. Mayer, K. Pritchard, T. Whelan, P. Rastogi, L. Shepherd (2011)
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agentsBreast Cancer Research and Treatment, 126
T. Ahern, L. Pedersen, M. Tarp, D. Cronin-Fenton, J. Garne, R. Silliman, H. Sørensen, T. Lash (2011)
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.Journal of the National Cancer Institute, 103 19
K. Liby (2013)
Abstract 1078: The efficacy of the PARP inhibitors olaparib and veliparib for prevention of breast cancer in a mouse model of BRCA1 deficiency.Cancer Research, 73
Veronica Shim, M. Gauthier, D. Sudilovsky, K. Mantei, K. Chew, D. Moore, I. Cha, T. Tlsty, L. Esserman (2003)
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.Cancer research, 63 10
B. Jiang, Ling-Zhi Liu (2009)
PI3K/PTEN signaling in angiogenesis and tumorigenesis.Advances in cancer research, 102
P. Goss, J. Ingle, J. Alés‐Martínez, A. Cheung, R. Chlebowski, J. Wactawski‐Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J. Garber, C. Fabian, P. Pujol, E. Maunsell, P. Farmer, K. Gelmon, D. Tu, H. Richardson (2011)
Exemestane for breast-cancer prevention in postmenopausal women.The New England journal of medicine, 364 25
(Gomez LS, Zancan P, Marcondes MC, Ramos-Santos L, Meyer-Fernandes JR, Sola-Penna M, Da Silva D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013.)
Gomez LS, Zancan P, Marcondes MC, Ramos-Santos L, Meyer-Fernandes JR, Sola-Penna M, Da Silva D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013.Gomez LS, Zancan P, Marcondes MC, Ramos-Santos L, Meyer-Fernandes JR, Sola-Penna M, Da Silva D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013., Gomez LS, Zancan P, Marcondes MC, Ramos-Santos L, Meyer-Fernandes JR, Sola-Penna M, Da Silva D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013.
R. Ariga, Adil Zarif, Jocelyn Korasick, V. Reddy, K. Siziopikou, P. Gattuso (2005)
Correlation of Her‐2/neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast CarcinomaThe Breast Journal, 11
(2006)
Chem Biol Interact
Debra Winkeljohn (2008)
Triple-negative breast cancer.Clinical journal of oncology nursing, 12 6
W. Farwell, R. Scranton, Elizabeth Lawler, R. Lew, M. Brophy, L. Fiore, J. Gaziano (2008)
The association between statins and cancer incidence in a veterans population.Journal of the National Cancer Institute, 100 2
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
R. Shaw, K. Lamia, Debbie Vasquez, S. Koo, N. Bardeesy, R. DePinho, M. Montminy, L. Cantley (2005)
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of MetforminScience, 310
P. Coogan, L. Rosenberg, J. Palmer, B. Strom, A. Zauber, S. Shapiro (2002)
Statin Use and the Risk of Breast and Prostate CancerEpidemiology, 13
M. Anzano, S. Byers, Joseph Smith, C. Peer, L. Mullen, C. Brown, A. Roberts, M. Sporn (1994)
Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen.Cancer research, 54 17
Yong-Xin Li, S. Himaya, Se-Kwon Kim (2013)
Triterpenoids of Marine Origin as Anti-Cancer AgentsMolecules, 18
E. John, A. Miron, G. Gong, A. Phipps, Anna Felberg, Frederick Li, D. West, A. Whittemore (2007)
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.JAMA, 298 24
(2008)
Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers. 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting
(2008)
Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers
A. Mazumdar, D. Medina, Francis Kittrell, Yun Zhang, Jamal Hill, David Edwards, R. Bissonnette, P. Brown (2012)
The Combination of Tamoxifen and the Rexinoid LG100268 Prevents ER-Positive and ER-Negative Mammary Tumors in p53-Null Mammary Gland MiceCancer Prevention Research, 5
U. Veronesi, G. Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. Turco, M. Mauro, M. Muraca, M. Vecchio, C. Pinto, G. D'Aiuto, C. Boni, T. Campa, A. Magni, R. Miceli, M. Perloff, W. Malone, M. Sporn (1999)
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.Journal of the National Cancer Institute, 91 21
J. Bosco, S. Antonsen, H. Sørensen, L. Pedersen, T. Lash (2010)
Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case–Control Study in DenmarkCancer Epidemiology, Biomarkers & Prevention, 20
K. Chiang, C. Yeh, Shin-Cheh Chen, S. Shen, J. Hsu, T. Yeh, Jong‐Hwei Pang, L. Su, M. Takano, A. Kittaka, H. Juang, Tai-Chi Chen (2012)
MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D3 in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer CellsEvidence-based Complementary and Alternative Medicine : eCAM, 2012
V. Vogel, V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2010)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 3
M. Bodmer, C. Meier, S. Krähenbühl, S. Jick, C. Meier (2010)
Long-Term Metformin Use Is Associated With Decreased Risk of Breast CancerDiabetes Care, 33
M. Weil, A. Chen (2011)
PARP inhibitor treatment in ovarian and breast cancer.Current problems in cancer, 35 1
R. Chlebowski, A. McTiernan, J. Wactawski‐Wende, J. Manson, A. Aragaki, T. Rohan, E. Ipp, V. Kaklamani, M. Vitolins, R. Wallace, M. Gunter, L. Phillips, H. Strickler, K. Margolis, D. Euhus (2012)
Diabetes, metformin, and breast cancer in postmenopausal women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 23
Mark Owen, E. Doran, A. Halestrap (2000)
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.The Biochemical journal, 348 Pt 3
J. Cuzick, I. Šestak, J. Forbes, M. Dowsett, Jill Knox, S. Cawthorn, C. Saunders, N. Roche, R. Mansel, G. Minckwitz, B. Bonanni, T. Palva, A. Howell (2014)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialThe Lancet, 383
M. El-Mir, V. Nogueira, É. Fontaine, N. Avéret, M. Rigoulet, X. Leverve (2000)
Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I*The Journal of Biological Chemistry, 275
A. Decensi, M. Puntoni, G. Pruneri, A. Guerrieri-Gonzaga, M. Lazzeroni, D. Serrano, D. Macis, H. Johansson, O. Pala, A. Luini, P. Veronesi, V. Galimberti, Maria Dotti, G. Viale, B. Bonanni (2011)
Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical TrialCancer Prevention Research, 4
P. Rothwell, Gerald Fowkes, J. Belch, H. Ogawa, C. Warlow, T. Meade (2011)
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 377
L. Castillo‐Pichardo, L. Cubano, S. Dharmawardhane (2013)
Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised miceBMC Complementary and Alternative Medicine, 13
K. Wada, Kozue Nakamura, Y. Tamai, M. Tsuji, Toshiaki Kawachi, Akihiro Hori, N. Takeyama, S. Tanabashi, Shogen Matsushita, N. Tokimitsu, C. Nagata (2013)
Soy isoflavone intake and breast cancer risk in Japan: From the Takayama studyInternational Journal of Cancer, 133
Pei Zhu, M. Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, S. Edgerton, L. Williams, A. Thor, Xiaohe Yang (2013)
Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer ModelsCancer Prevention Research, 7
D. Medina, F. Kittrell, Jamal Hill, Yun Zhang, S. Hilsenbeck, R. Bissonette, P. Brown (2009)
Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and CelecoxibCancer Prevention Research, 2
(Brown PH, Arun B, Miller A, Isaacs C, Gutierrez C, et al.: Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers. 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting, Chicago, 2008: p 178–79 2008.)
Brown PH, Arun B, Miller A, Isaacs C, Gutierrez C, et al.: Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers. 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting, Chicago, 2008: p 178–79 2008.Brown PH, Arun B, Miller A, Isaacs C, Gutierrez C, et al.: Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers. 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting, Chicago, 2008: p 178–79 2008., Brown PH, Arun B, Miller A, Isaacs C, Gutierrez C, et al.: Phase II trial of bexarotene in wormen at high risk of breast cancer, comparison of protein and RNA biomarkers. 7th Annual AACR International Frontiers in Cancer Prevention Research Meeting, Chicago, 2008: p 178–79 2008.
F. Xue, K. Michels (2007)
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence.The American journal of clinical nutrition, 86 3
W. Foulkes, I. Smith, J. Reis-Filho (2010)
Triple-negative breast cancer.The New England journal of medicine, 363 20
Kendall Wu, Heetae Kim, J. Rodriquez, D. Muñoz-Medellin, S. Mohsin, S. Hilsenbeck, W. Lamph, M. Gottardis, M. Shirley, J. Kuhn, J. Green, P. Brown (2000)
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 9
V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, S. Lippman, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
S. Niraula, R. Dowling, M. Ennis, Martin Chang, S. Done, N. Hood, J. Escallon, W. Leong, D. McCready, M. Reedijk, V. Stambolic, P. Goodwin (2012)
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant studyBreast Cancer Research and Treatment, 135
Kendall Wu, E. Dupré, Heetae Kim, C. Tin-U, R. Bissonnette, W. Lamph, P. Brown (2006)
Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockadeBreast Cancer Research and Treatment, 96
(Zhu P, Davis M, Blackwelder A, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin Selectively Targets Tumor Initiating Cells in erbB-2 Overexpressing Breast Cancer Models. Cancer Prev Res (Phila) 2013.)
Zhu P, Davis M, Blackwelder A, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin Selectively Targets Tumor Initiating Cells in erbB-2 Overexpressing Breast Cancer Models. Cancer Prev Res (Phila) 2013.Zhu P, Davis M, Blackwelder A, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin Selectively Targets Tumor Initiating Cells in erbB-2 Overexpressing Breast Cancer Models. Cancer Prev Res (Phila) 2013., Zhu P, Davis M, Blackwelder A, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin Selectively Targets Tumor Initiating Cells in erbB-2 Overexpressing Breast Cancer Models. Cancer Prev Res (Phila) 2013.
Y. Vinogradova, C. Coupland, J. Hippisley-Cox (2011)
Exposure to statins and risk of common cancers: a series of nested case-control studiesBMC Cancer, 11
(Liby KT. Abstract 1078: The efficacy of the PARP inhibitors olaparib and veliparib for prevention of breast cancer in a mouse model of BRCA1 deficiency. Cancer Research 2013, 73(8).)
Liby KT. Abstract 1078: The efficacy of the PARP inhibitors olaparib and veliparib for prevention of breast cancer in a mouse model of BRCA1 deficiency. Cancer Research 2013, 73(8).Liby KT. Abstract 1078: The efficacy of the PARP inhibitors olaparib and veliparib for prevention of breast cancer in a mouse model of BRCA1 deficiency. Cancer Research 2013, 73(8)., Liby KT. Abstract 1078: The efficacy of the PARP inhibitors olaparib and veliparib for prevention of breast cancer in a mouse model of BRCA1 deficiency. Cancer Research 2013, 73(8).
I. Berquin, I. Edwards, Yong Chen (2008)
Multi-targeted therapy of cancer by omega-3 fatty acids.Cancer letters, 269 2
S. Friis, A. Poulsen, S. Johnsen, J. Mclaughlin, J. Fryzek, S. Dalton, H. Sørensen, J. Olsen (2005)
Cancer risk among statin users: A population‐based cohort studyInternational Journal of Cancer, 114
A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy
J. Cauley, A. McTiernan, R. Rodabough, A. LaCroix, D. Bauer, K. Margolis, E. Paskett, M. Vitolins, C. Furberg, R. Chlebowski (2006)
Statin use and breast cancer: prospective results from the Women's Health Initiative.Journal of the National Cancer Institute, 98 10
L. Howe, K. Subbaramaiah, J. Patel, J. Masferrer, A. Deora, C. Hudis, H. Thaler, W. Muller, B. Du, A. Brown, A. Dannenberg (2002)
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.Cancer research, 62 19
(Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des 2013.)
Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des 2013.Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des 2013., Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des 2013.
Chunhua Lu, C. Speers, Yun Zhang, Xiaochun Xu, Jamal Hill, Emily Steinbis, J. Celestino, Q. Shen, Heetae Kim, S. Hilsenbeck, S. Mohsin, A. Wakeling, C. Osborne, P. Brown (2004)
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.Journal of the National Cancer Institute, 95 24
K. Liby, R. Risingsong, Darlene Royce, Charlotte Williams, M. Yore, T. Honda, G. Gribble, W. Lamph, N. Vannini, I. Sogno, A. Albini, M. Sporn (2008)
Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268Clinical cancer research : an official journal of the American Association for Cancer Research, 14
M. Piechocki, Susan Dibbley, F. Lonardo, G. Yoo (2007)
Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neuInternational Journal of Cancer, 122
S. Safe, P. Prather, L. Brents, Gayathri Chadalapaka, Indira Jutooru (2012)
Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs.Anti-cancer agents in medicinal chemistry, 12 10
D. Sabatini (2006)
mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 6
P. Hollander, Michelle Savage, P. Brown (2013)
Targeted Therapy for Breast Cancer PreventionFrontiers in Oncology, 3
Kendall Wu, Heetae Kim, J. Rodriquez, S. Hilsenbeck, S. Mohsin, Xìao-chun Xu, W. Lamph, J. Kuhn, Jeffrey Green, P. Brown (2002)
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 11 5
F. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. Yocum, C. Osborne, D. Hayes, G. Hortobagyi, E. Winer, G. Demetri (2003)
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 6
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss (2010)
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenJ Clin Oncol, 28
T. Staa, T. Staa, D. Patel, A. Gallagher, A. Gallagher, M. Bruin (2012)
Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care dataDiabetologia, 55
V. Anisimov, P. Egormin, T. Piskunova, I. Popovich, M. Tyndyk, M. Yurova, M. Zabezhinski, I. Anikin, A. Karkach, A. Romanyukha (2010)
Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivoCell Cycle, 9
W. Hong, S. Lippman, L. Itri, D. Karp, J. Lee, R. Byers, S. Schantz, A. Kramer, R. Lotan, L. Peters, I. Dimery, B. Brown, H. Goepfert (1990)
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.The New England journal of medicine, 323 12
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
B. Bonanni, M. Puntoni, M. Cazzaniga, G. Pruneri, D. Serrano, A. Guerrieri-Gonzaga, A. Gennari, Maria Trabacca, V. Galimberti, P. Veronesi, H. Johansson, Valentina Aristarco, F. Bassi, A. Luini, M. Lazzeroni, C. Varricchio, G. Viale, P. Bruzzi, A. Decensi (2012)
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
G. Hortobagyi, P. Brown (2010)
Two Good Choices to Prevent Breast Cancer: Great Taste, Less FillingCancer Prevention Research, 3
A. Eliassen, Sara Hendrickson, L. Brinton, Julie Buring, H. Campos, Q. Dai, J. Dorgan, A. Franke, Yu-Tang Gao, Marc Goodman, G. Hallmans, K. Helzlsouer, J. Hoffman-Bolton, K. Hultén, H. Sesso, Anne Sowell, R. Tamimi, P. Toniolo, Lynne Wilkens, A. Winkvist, A. Zeleniuch‐Jacquotte, W. Zheng, S. Hankinson (2012)
Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies.Journal of the National Cancer Institute, 104 24
K. Soprano, D. Soprano (2002)
Retinoic acid receptors and cancer.The Journal of nutrition, 132 12
E. Jacobs, C. Newton, M. Thun, S. Gapstur (2010)
Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.Cancer research, 71 5
(Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer [[http://clinicaltrials.gov/ct2/show/NCT01589367?term=han+metformin+breast&rank=1])
Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer [[http://clinicaltrials.gov/ct2/show/NCT01589367?term=han+metformin+breast&rank=1]Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer [[http://clinicaltrials.gov/ct2/show/NCT01589367?term=han+metformin+breast&rank=1], Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer [[http://clinicaltrials.gov/ct2/show/NCT01589367?term=han+metformin+breast&rank=1]
R. Brandão, J. Veeck, K. Vijver, P. Lindsey, B. Vries, C. Elssen, M. Blok, K. Keymeulen, T. Ayoubi, H. Smeets, V. Tjan-Heijnen, P. Hupperets (2013)
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancerBreast Cancer Research : BCR, 15
Yuxin Li, Yun Zhang, Jamal Hill, Q. Shen, Heetae Kim, Xìao-chun Xu, S. Hilsenbeck, R. Bissonnette, W. Lamph, P. Brown (2007)
The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 MiceClinical Cancer Research, 13
(A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. [ http://clinicaltrials.gov/show/NCT01101438])
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. [ http://clinicaltrials.gov/show/NCT01101438]A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. [ http://clinicaltrials.gov/show/NCT01101438], A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. [ http://clinicaltrials.gov/show/NCT01101438]
V. Seewaldt, Ji-Hyon Kim, Leslie Caldwell, Barton Johnson, K. Swisshelm, S. Collins (1997)
All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 8 6
J. Thigpen (2010)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenYearbook of Medicine, 2010
(Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013.)
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013.Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013., Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013.
(Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer [http://clinicaltrials.gov/ct2/show/record/NCT01905046?term=phase+III+metformin+breast&rank=2])
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer [http://clinicaltrials.gov/ct2/show/record/NCT01905046?term=phase+III+metformin+breast&rank=2]Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer [http://clinicaltrials.gov/ct2/show/record/NCT01905046?term=phase+III+metformin+breast&rank=2], Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer [http://clinicaltrials.gov/ct2/show/record/NCT01905046?term=phase+III+metformin+breast&rank=2]
N. Mongan, L. Gudas (2007)
Diverse actions of retinoid receptors in cancer prevention and treatment.Differentiation; research in biological diversity, 75 9
Eun-Hee Kim, C. Deng, M. Sporn, Darlene Royce, R. Risingsong, Charlotte Williams, K. Liby (2011)
CDDO-Methyl Ester Delays Breast Cancer Development in Brca1-Mutated MiceCancer Prevention Research, 5
C. Meads, I. Ahmed, R. Riley (2012)
A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performanceBreast Cancer Research and Treatment, 132
C. Mandal, N. Ghosh-Choudhury, T. Yoneda, G. Choudhury, N. Ghosh‐Choudhury (2011)
Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44*The Journal of Biological Chemistry, 286
Mei Liu, Amy Howes, Jacqueline Lesperance, W. Stallcup, C. Hauser, K. Kadoya, R. Oshima, R. Abraham (2005)
Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.Cancer research, 65 12
J. Uzoigwe, E. Sauter (2012)
Cancer prevention and treatment using combination therapy with plant- and animal-derived compoundsExpert Review of Clinical Pharmacology, 5
P. Goodwin, Kathleen Pritchard, Kathleen Pritchard, M. Ennis, M. Clemons, M. Graham, I. Fantus, I. Fantus (2008)
Insulin-lowering effects of metformin in women with early breast cancer.Clinical breast cancer, 8 6
M. Higgins, Tatiana Prowell, A. Blackford, C. Byrne, N. Khouri, S. Slater, S. Jeter, D. Armstrong, N. Davidson, L. Emens, J. Fetting, Pendleton Powers, A. Wolff, H. Green, Jacklyn Thibert, J. Rae, E. Folkerd, M. Dowsett, R. Blumenthal, J. Garber, V. Stearns (2012)
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancerBreast Cancer Research and Treatment, 131
S. Hadad, T. Iwamoto, L. Jordan, C. Purdie, S. Bray, L. Baker, G. Jellema, S. Deharo, D. Hardie, L. Pusztai, S. Moulder-Thompson, J. Dewar, Alastair Thompson, Alastair Thompson (2011)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trialBreast Cancer Research and Treatment, 128
Md. Khan, Han-chun Chen, Xin-Xing Wan, Mousumi Tania, A. Xu, Fang-zhi Chen, Dian-zheng Zhang (2013)
Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cellsMolecules and Cells, 35
Qi Xie, Ming‐liang Chen, Yu Qin, Qian‐yong Zhang, Hong-xia Xu, Y. Zhou, Man‐tian Mi, Jun‐dong Zhu (2013)
Isoflavone consumption and risk of breast cancer: a dose-response meta-analysis of observational studies.Asia Pacific journal of clinical nutrition, 22 1
G. Kong, Heetae Kim, Kendall Wu, D. DeNardo, S. Hilsenbeck, Xìao-chun Xu, W. Lamph, R. Bissonnette, A. Dannenberg, P. Brown (2005)
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.Cancer research, 65 8
Kai Chan, W. Knox, J. Gee, Julie Morris, R. Nicholson, C. Potten, N. Bundred (2002)
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.Cancer research, 62 1
S. Woditschka, J. Haag, J. Waller, D. Monson, Andrew Hitt, Heidi Brose, R. Hu, Yun Zheng, Philip Watson, Kwanghee Kim, M. Lindstrom, B. Mau, V. Steele, R. Lubet, M. Gould (2006)
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.Cancer research, 66 13
J. So, Amanda Smolarek, David Salerno, H. Maehr, M. Uskoković, Fang Liu, N. Suh (2013)
Targeting CD44-STAT3 Signaling by Gemini Vitamin D Analog Leads to Inhibition of Invasion in Basal-Like Breast CancerPLoS ONE, 8
Y. Iino, T. Karakida, N. Sugamata, T. Andoh, H. Takei, M. Takahashi, S. Yaguchi, T. Matsuno, M. Takehara, M. Sakato, S. Kawashima, Y. Morishita (1998)
Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.Anticancer research, 18 1A
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
I. Uray, Q. Shen, H. Seo, Heetae Kim, W. Lamph, R. Bissonnette, P. Brown (2009)
Rexinoid-induced Expression of IGFBP-6 Requires RARβ-dependent Permissive Cooperation of Retinoid Receptors and AP-1*Journal of Biological Chemistry, 284
Md. Khan, Han-chun Chen, Xin-Xing Wan, Mousumi Tania, A. Xu, Fang-zhi Chen, Dianzheng Zhang (2013)
Erratum to “Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells”Molecules and Cells, 35
G. Peoples, J. Gurney, M. Hueman, M. Woll, G. Ryan, C. Storrer, C. Fisher, C. Shriver, C. Ioannides, S. Ponniah (2005)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
Limin Yang, J. Ostrowski, P. Reczek, P. Brown (2001)
The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFβ and causing cell cycle arrestOncogene, 20
L. Wright, J. Frye, Bhavana Gorti, B. Timmermann, J. Funk (2013)
Bioactivity of turmeric-derived curcuminoids and related metabolites in breast cancer.Current pharmaceutical design, 19 34
C. Grubbs, R. Lubet, V. Atigadda, K. Christov, A. Deshpande, Vivek Tirmal, G. Xia, K. Bland, I. Eto, W. Brouillette, D. Muccio (2006)
Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.Carcinogenesis, 27 6
S. Lanza‐Jacoby, Sheldon Miller, J. Flynn, Kathleen Gallatig, C. Daskalakis, J. Masferrer, B. Zweifel, H. Sembhi, I. Russo (2003)
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 12 12
X. He, F. Esteva, J. Ensor, G. Hortobagyi, Mong-Hong Lee, Sai-Ching Yeung (2012)
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 23 7
R. Zoncu, A. Efeyan, D. Sabatini (2010)
mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 12
S. Bonovas, K. Filioussi, N. Tsavaris, N. Sitaras (2005)
Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
K. Undela, V. Srikanth, D. Bansal (2012)
Statin use and risk of breast cancer: a meta-analysis of observational studiesBreast Cancer Research and Treatment, 135
B. Fisher, J. Costantino, D. Wickerham, C. Redmond, M. Kavanah, W. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-chiu, L. Ford, N. Wolmark (1999)
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.Journal of the National Cancer Institute, 90 18
(Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, Zhang DZ. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013.)
Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, Zhang DZ. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013.Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, Zhang DZ. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013., Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, Zhang DZ. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013.
(Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation [http://clinicaltrials.gov/ct2/show/NCT00930579?term=hershman+metformin+breast&rank=1])
Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation [http://clinicaltrials.gov/ct2/show/NCT00930579?term=hershman+metformin+breast&rank=1]Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation [http://clinicaltrials.gov/ct2/show/NCT00930579?term=hershman+metformin+breast&rank=1], Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation [http://clinicaltrials.gov/ct2/show/NCT00930579?term=hershman+metformin+breast&rank=1]
P. Brown, K. Subbaramaiah, Amoi Salmon, Rebecca Baker, R. Newman, Peiying Yang, X. Zhou, R. Bissonnette, A. Dannenberg, L. Howe (2008)
Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor–Selective RetinoidCancer Prevention Research, 1
Xiao-Han Tang, L. Gudas (2011)
Retinoids, retinoic acid receptors, and cancer.Annual review of pathology, 6
S. Vinayak, E. Schwartz, K. Jensen, J. Lipson, E. Alli, L. McPherson, Adrian Fernandez, Vandana Sharma, A. Staton, M. Mills, E. Schackmann, M. Telli, Ani Kardashian, J. Ford, A. Kurian (2013)
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer riskBreast Cancer Research and Treatment, 142
Lilian Gomez, P. Zancan, M. Marcondes, Livia Ramos-Santos, J. Meyer‐Fernandes, M. Sola-Penna, D. Silva (2013)
Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase.Biochimie, 95 6
H. Kuerer, A. Buzdar, E. Mittendorf, F. Esteva, A. Lucci, L. Vence, L. Radvanyi, F. Meric-Bernstam, K. Hunt, W. Symmans (2011)
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastCancer, 117
Pei Zhu, M. Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, S. Edgerton, L. Williams, A. Thor, Xiaohe Yang (2014)
Abstract 2967: Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer modelsCancer Research, 74
P. Autier, M. Boniol, C. Lavecchia, L. Vatten, A. Gavin, C. Héry, M. Heanue (2010)
Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality databaseThe BMJ, 341
U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. Mauro, Aurora Costa, E. Marubini, M. Sporn, G. Palo (2006)
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 17 7
S. Nickels, A. Vrieling, P. Seibold, J. Heinz, N. Obi, D. Flesch-Janys, J. Chang-Claude (2013)
Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient CohortPLoS ONE, 8
E. Garwood, E. Garwood, Anjali Kumar, Fl Baehner, D. Moore, A. Au, N. Hylton, C. Flowers, J. Garber, B. Lesnikoski, E. Hwang, O. Olopade, E. Port, M. Campbell, L. Esserman (2009)
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancerBreast Cancer Research and Treatment, 119
G. Peoples, J. Holmes, M. Hueman, E. Mittendorf, Asna Amin, S. Khoo, Z. Dehqanzada, J. Gurney, Michael Woll, G. Ryan, C. Storrer, D. Craig, C. Ioannides, S. Ponniah (2008)
Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 14
C. Grubbs, D. Hill, K. Bland, S. Beenken, Tsu-Han Lin, I. Eto, V. Atigadda, Kimberly Vines, W. Brouillette, D. Muccio (2003)
9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.Cancer letters, 201 1
X-H Tang, LJ Gudas (2011)
Retinoids, Retinoic Acid Receptors, and CancerAnn Rev Pathol Mech Dis, 6
B. Weigelt, J. Reis-Filho (2009)
Histological and molecular types of breast cancer: is there a unifying taxonomy?Nature Reviews Clinical Oncology, 6
Caterina Catania, Caterina Catania, Elke Binder, Elke Binder, Daniela Cota, Daniela Cota (2011)
mTORC1 signaling in energy balance and metabolic diseaseInternational Journal of Obesity, 35
(Vitamin D and Omega-3 Trial (VITAL) [http://clinicaltrials.gov/show/NCT01169259])
Vitamin D and Omega-3 Trial (VITAL) [http://clinicaltrials.gov/show/NCT01169259]Vitamin D and Omega-3 Trial (VITAL) [http://clinicaltrials.gov/show/NCT01169259], Vitamin D and Omega-3 Trial (VITAL) [http://clinicaltrials.gov/show/NCT01169259]
I. Mercier, J. Camacho, Kanani Titchen, Donna Gonzales, K. Quann, Kelly Bryant, A. Molchansky, Janet Milliman, D. Whitaker‐Menezes, F. Sotgia, J. Jasmin, R. Schwarting, R. Pestell, M. Blagosklonny, M. Lisanti (2012)
Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.The American journal of pathology, 181 1
R. Samy, P. Gopalakrishnakone, S. Ignacimuthu (2006)
Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.Chemico-biological interactions, 164 1-2
N. Hynes, H. Lane (2005)
ERBB Receptors and Cancer: The Complexity of Targeted InhibitorsNature Reviews Cancer, 5
A. Agrawal, I. Fentiman (2008)
NSAIDs and breast cancer: a possible prevention and treatment strategyInternational Journal of Clinical Practice, 62
(A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy [http://clinicaltrials.gov/ct2/show/NCT01266486?term=Harris+metformin+breast&rank=1])
A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy [http://clinicaltrials.gov/ct2/show/NCT01266486?term=Harris+metformin+breast&rank=1]A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy [http://clinicaltrials.gov/ct2/show/NCT01266486?term=Harris+metformin+breast&rank=1], A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy [http://clinicaltrials.gov/ct2/show/NCT01266486?term=Harris+metformin+breast&rank=1]
Tracy Strecker, Q. Shen, Yun Zhang, Jamal Hill, Yuxin Li, Chunyu Wang, Heetae Kim, T. Gilmer, Krystal Sexton, S. Hilsenbeck, C. Osborne, Powel Brown (2009)
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.Journal of the National Cancer Institute, 101 2
D. Tran‐Thanh, Stephen Buttars, Y. Wen, Christine Wilson, S. Done (2010)
Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse ModelCancer Prevention Research, 3
(2014)
Curr Breast Cancer Rep
J. Cuzick, A. Decensi, B. Arun, P. Brown, M. Castiglione, B. Dunn, J. Forbes, A. Glaus, A. Howell, G. Minckwitz, V. Vogel, H. Zwierzina (2011)
Preventive therapy for breast cancer: a consensus statement.The Lancet. Oncology, 12 5
N. Ghosh-Choudhury, C. Mandal, N. Ghosh‐Choudhury, G. Choudhury (2010)
Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth.Cellular signalling, 22 5
J. Cuzick, I. Šestak, M. Baum, A. Buzdar, A. Howell, M. Dowsett, J. Forbes (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.The Lancet. Oncology, 11 12
A. Arcaro (2013)
Targeting the insulin-like growth factor-1 receptor in human cancerFrontiers in Pharmacology, 4
R. Siegel, D. Naishadham, A. Jemal (2013)
Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 63
R. Moon, H. Thompson, P. Becci, C. Grubbs, R. Gander, D. Newton, J. Smith, S. Phillips, W. Henderson, L. Mullen, C. Brown, M. Sporn (1979)
N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.Cancer research, 39 4
Ho-Young Lee, Marcia Dawson, Garrett Walsh, Jonathan Nesbitt, Richard Eckert, Elaine Fuchs, W. Hong, R. Lotan, J. Kurie (1996)
Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 7 8
L. Yang, J. Ostrowski, P. Reczek, P. Brown (2001)
The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest.Oncogene, 20 55
Preventing breast cancer is an effective strategy for reducing breast cancer deaths. The purpose of chemoprevention (also termed preventive therapy) is to reduce cancer incidence by use of natural, synthetic, or biological agents. The efficacy of tamoxifen, raloxifene, and exemestane as preventive therapy against estrogen-receptor (ER)-positive breast cancer is well established for women at increased risk for breast cancer. However, because breast cancer is a heterogeneous disease, distinct preventive approaches may be required for effective prevention of each subtype. Current research is, therefore, focused on identifying alternative mechanisms by which biologically active compounds can reduce the risk of all breast cancer subtypes including ER-negative breast cancer. Promising agents are currently being developed for prevention of HER2-positive and triple-negative breast cancer (TNBC) and include inhibitors of the ErbB family receptors, COX-2 inhibitors, metformin, retinoids, statins, poly(ADP-ribose) polymerase inhibitors, and natural compounds. This review focuses on recent progress in research to develop more effective preventive agents, in particular for prevention of ER-negative breast cancer.
Current Breast Cancer Reports – Springer Journals
Published: Mar 25, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.